Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus

Viral Immunology

Volumn 20, Issue 4, 2007, Pages 657-663

  Amexis, Georgios ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EPITOPE; GLYCOPROTEIN E; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; COMPUTER PROGRAM; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; VIRUS INFECTIVITY;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; PLAQUE ASSAY; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

DENGUE VIRUS TYPE 2; MUS;

EID: 37549034210     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0029     Document Type: Article

References (41)

1. Basak A, Boudreault A, Chen A, Chretien M, Seidah NG, and Lazure C: Application of the multiple antigenic peptides (MAP) strategy to the production of prohormone convertases antibodies: synthesis, characterization and use of 8-branched immunogenic peptides. J Pept Sci 1995;1:385-395.
2. Chang GJ, Kuno G, Purdy DE, and Davis BS: Recent advancement in flavivirus vaccine development. Expert Rev Vaccines 2004;3:199-220.
3. Crill WD, and Roehrig JT: Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001;75:7769-7773.
4. Ghosh S, and Jackson DC: Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Int Immunol 1999;11:1103-1110.
5. Guirakhoo F, Pugachev K, Zhang Z, et al.: Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78:4761-4775.
6. Guzman MG, Mune M, and Kouri G: Dengue vaccine: priorities and progress. Expert Rev Anti Infect Ther 2004;2: 895-911.
7. Halstead SB, Heinz FX, Barrett AD, and Roehrig JT: Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine 2005;23: 849-856.
8. Haro I, and Gomara MJ: Different approaches to potentiate the immune response induced by a 12-mer synthetic peptide. Curr Protein Pept Sci 2000;1:125-137.
9. Haro I, Perez S, Garcia M, Chan WC, and Ercilla G: Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design. FEBS Lett 2003;540:133-140.
10. Hombach J, Barrett AD, Cardosa MJ, et al.: Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2005;23:2689-2695.
11. Hopp TP, and Woods KR: Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 1981;78:3824-3828.
12. Kinney RM, and Huang CY: Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 2001;44:176-197.
13. Kochel TJ, Raviprakash K, Hayes CG, et al.: A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000;18:3166-3173.
14. Leclerc C, Deriaud E, Megret F, Briand JP, Van Regenmortel MH, and Deubel V: Identification of helper T cell epitopes of dengue virus E-protein. Mol Immunol 1993;30: 613-625.
15. Lin B, Parrish CR, Murray JM, and Wright PJ: Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 1994;202:885-890.
16. Malavige GN, Fernando S, Fernando DJ, and Seneviratne SL: Dengue viral infections. Postgrad Med J 2004;80: 588-601.
17. Mathew A, Kurane I, Green S, et al.: Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol 1998;72:3999-4004.
18. Modis Y, Ogata S, Clements D, and Harrison SC: Structure of the dengue virus envelope protein after membrane fusion. Nature 2004;427:313-319.
19. Modis Y, Ogata S, Clements D, and Harrison SC: A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003;100:6986-6991.
20. Modis Y, Ogata S, Clements D, and Harrison SC: Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005;79:1223-1231.
21. Morens DM: Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994;19:500-512.
22. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr., and Gerhard W: Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003;21:2616-2626.
23. Olive C, Toth I, and Jackson D: Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem 2001;1:429-438.
24. Ota S, Ono T, Morita A, Uenaka A, Harada M, and Nakayama E: Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells. Cancer Res 2002;62:1471-1476.
25. Purcell AW, Zeng W, Mifsud NA, Ely LK, Macdonald WA, and Jackson DC: Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J Pept Sci 2003;9:255-281.
26. Putnak R, Fuller J, VanderZanden L, Innis BL, and Vaughn DW: Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral premembrane and envelope genes. Am J Trop Med Hyg 2003;68:469-476.
27. Raviprakash K, Porter KR, Kochel TJ, et al.: Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000;81:1659-1667.
28. Rico-Hesse R: Microevolution and virulence of dengue viruses. Adv Virus Res 2003;59:315-341.
29. Roehrig JT, Risi PA, Brubaker JR, Hunt AR, Beaty BJ, Trent DW, and Mathews JH: T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 1994; 198:31-38.
30. Roehrig JT, Johnson AJ, Hunt AR, Bolin RA, and Chu MC: Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology 1990;177: 668-675.
31. Roehrig JT, Bolin RA, and Kelly RG: Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998;246:317-328.
32. Rothman AL: Dengue: defining protective versus pathologic immunity. J Clin Invest 2004;113:946-951.
33. Schiavetta AM, Harre JG, Wagner E, Simmons M, and Raviprakash K: Variable susceptibility of the owl monkey (Aotus nancymae) to four serotypes of dengue virus. Contemp Top Lab Anim Sci 2003;42:12-20.
34. Seligman SJ, and Gould EA: Live flavivirus vaccines: reasons for caution. Lancet 2004;363:2073-2075.
35. Sun W, Edelman R, Kanesa-Thasan N, et al.: Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003;69(6 Suppl):24-31.
36. Thullier P, Demangel C, Bedouelle H, et al.: Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 2001;82:1885-1892.
37. Van Regenmortel MHV: Mapping epitope structure and activity: From one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 1996; 9:465-472.
38. Vasconcelos NM, Siddique AB, Ahlborg N, and Berzins K: Differential antibody responses to Plasmodium falciparum-derived B-cell epitopes induced by diepitope multiple antigen peptides (MAP) containing different T-cell epitopes. Vaccine 2004;23:343-352.
39. Welling GW, Weijer WJ, van der Zee R, and Welling-Wester S: Prediction of sequential antigenic regions in proteins. FEBS Lett 1985;188:215-218.
40. Zhang Y, Zhang W, Ogata S, et al.: Conformational changes of the flavivirus E glycoprotein. Structure 2004; 12:1607-1618.
41. Zivna I, Green S, Vaughn DW, et al.: T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 2002; 168:5959-5965.